Gilead announced it will acquire Ouro Medicines for about $2.17 billion, adding the autoimmune-stage BCMAxCD3 T-cell engager gamgertamig (OM336). The front-loaded structure includes $1.675 billion in upfront cash plus up to $500 million in contingent milestone payments, with Galapagos expected to remain involved through a deal-aligned alliance. The asset is designed to deliver rapid and deep B-cell depletion via a limited subcutaneous treatment course, with early clinical work reported in autoimmune hemolytic anemia and immune thrombocytopenia. Gilead said it is also aligning the acquisition with a broader immunology portfolio strategy, while the partnership structure underscores the complexity of bispecific integration across developers and collaborators. Regulatory designations reported for gamgertamig include Fast Track and Orphan Drug, setting up registrational planning targeted for the 2027 timeframe.